MARLBOROUGH, Mass.,
April 27, 2015 /PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) announces a collaboration with
Brainlab AG, a leading software-driven medical technology company
that helps improve patient treatment planning and surgical
navigation. The collaboration provides patients and physicians a
comprehensive portfolio for Deep Brain Stimulation (DBS) therapy.
DBS is intended to treat a variety of disorders, and most commonly
may help reduce symptoms for movement disorders such as Parkinson's
disease (PD), dystonia, and essential tremor. As part of the
agreement, Boston Scientific will begin distributing the Brainlab
DBS surgical planning portfolio with the Boston Scientific Vercise™
DBS System in select countries.
"Planning and visualization are important parts of the DBS
process and enable more precise placement for better patient
outcomes," said Maulik Nanavaty,
president, Neuromodulation, Boston Scientific. "As we continue to
invest in product development, clinical science, and solutions
services in the DBS therapy space, we have found natural synergies
with Brainlab. This collaboration offers physicians and their
patients advanced device technology as well as sophisticated
software capabilities."
DBS therapy involves the placement of a device that stimulates
specific areas of the brain using electrical signals. The Vercise
DBS System incorporates multiple independent current control, which
stimulates targeted areas in the brain selectively and is designed
to provide physicians with precise stimulation management.
"Our collaboration with Boston Scientific is a harmonious fit
given the complementary nature of our innovative portfolios and
shared passion for technology," said Stephan Holl, chief operating officer, Brainlab.
"Our joint solutions will streamline and integrate DBS treatments
for physicians and their patients and will also serve as a future
platform to further increase the access to and consistency of
care."
Brainlab was founded in Munich
in 1989 and supports treatments in radiosurgery as well as numerous
surgical fields including neurosurgery; orthopedic; ear, nose, and
throat (ENT); craniomaxillofacial (CMF); spine, and trauma. The
company has over 8,900 systems installed in about 100
countries.
The Vercise DBS System has CE Mark and is available in
Europe, Israel, Australia and certain countries in
Latin America and Asia Pacific for the treatment of PD, tremor
and dystonia. In the U.S., the Vercise DBS System is
investigational and not available for use or sale. The
INTREPID clinical trial is currently enrolling patients in the
U.S., evaluating the safety and effectiveness of the Vercise DBS
System for the treatment of PD.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For
more information, visit www.bostonscientific.com and connect on
Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements
are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be
guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our business plans, our collaboration with Brainlab AG
and its impact, and product performance and impact. If our
underlying assumptions turn out to be incorrect, or if certain
risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in
some cases, have affected and in the future (together with other
factors) could affect our ability to implement our business
strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking
statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions;
and, future business decisions made by us and our competitors.
All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a
further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, which we
may update in Part II, Item 1A – Risk Factors in Quarterly Reports
on Form 10-Q we have filed or will file hereafter. We
disclaim any intention or obligation to publicly update or revise
any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this
document.
CONTACT:
Media: Nisha Deo
Media Relations
Boston Scientific Corporation
408-893-9243 (cell)
Nisha.Deo@bsci.com
Investors: Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
508-683-5565 (office)
investor_relations@bsci.com
Indications for Use. The Vercise™ Deep Brain Stimulation (DBS)
System is indicated for use in unilateral or bilateral stimulation
of the subthalamic nucleus (STN) or internal globus pallidus (GPi)
for treatment of levodopa responsive Parkinson's disease which is
not adequately controlled with medication and also for treatment of
intractable primary and secondary dystonia, for persons 7 years of
age and older.
Prescriptive Information. All cited trademarks are the property
of their respective owners. CAUTION: The law restricts these
devices to sale by or on the order of a physician. Indications,
contraindications, warnings and instructions for use can be found
in the product labeling supplied with each device. Information for
the use only in countries with applicable health authority product
registrations.
© 2015 Boston Scientific Corporation or its affiliates.
All rights reserved.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-strategic-collaboration-with-brainlab-ag-300072732.html
SOURCE Boston Scientific Corporation